Determinants of delayed antenatal visit attendance in rural Burkina Faso: a cross-sectional study.

BMC Pregnancy ChildbirthOct 3, 2026 (epub)
Clinical ResearchObstetrics & GynecologyPreventive Medicine / Public HealthOpen access

Joël D Bognini, Toussaint Rouamba, Helen Brotherton et al.

✦ AI-curated · Sources linked

In 30 seconds

This cross-sectional study assessed delayed antenatal care (ANC) attendance among pregnant women in rural Burkina Faso. Out of 2480 women with data, 90.6% attended their first ANC visit after the 14th week of gestation. Key risk factors included multiparity of four or more pregnancies (OR = 2.26) and attending during the dry season (OR = 1.79).

Key findings

  • 90.6% of women attended their first ANC visit after the 14th week of gestation.
  • Multiparity of four or more pregnancies was associated with increased delay (OR = 2.26).
  • Attending ANC during the dry season was linked to delayed visits (OR = 1.79).

Why it matters

Delayed attendance for antenatal care can lead to poorer maternal and perinatal outcomes. Understanding the factors influencing this delay is crucial for developing targeted interventions to improve timely access to care.

Source

PubMed · PMID 42829441Free full text on PubMed Central

Published in BMC Pregnancy Childbirth. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.